Clinical Trial

Metformin in Safety and Efficacy in Gouty Patients

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The most frequent crystal arthropathy is gout, which is also the most prevalent cause of inflammatory arthritis. Gouty Patients frequently have excruciating pain and swelling in their joints. Gout is linked to decreased health-related quality of life and functional disability. Gout and its associated diseases have been shown to have a significant impact on patients mortality and morbidities. Metformin, a biguanide, is used to manage diabetes by reducing insulin resistance and preventing comorbidities such as cerebrovascular and coronary artery disease, as well as providing renal protection to diabetic nephropathy patients
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-05.
Status change: Not Yet Recruiting → Recruiting 2025-06-25
Trial Details
NCT Number NCT06924658
Lead Sponsor Mostafa Bahaa
Conditions Gout
Enrollment 70 participants
Start Date 2025-04-20
Primary Completion 2026-11-20 (estimated)
Study Completion 2026-11-20 (estimated)
Updated on ClinicalTrials.gov 2025-06-27